[Role of intravascular brachytherapy in the prevention of vascular restenosis after angioplasty].
About 30% of patients who underwent percutaneous transluminal coronary angioplasty show evidence of restenosis, which appears to be independent of the angioplasty method used. The restenosis is due of two factors, firstly migration of smooth vascular muscle cells of the vascular media to the intima and multiplication which lead to the formation of a neo-intima. Irradiation limits the proliferation by acting of the cells in the mitotic stage. The vascular target volume is not very thick and is difficult to define it, that why brachytherapy seems to be the best procedure to prevent restenosis. However, the development of this treatment present many difficulties. Different irradiation techniques have been studied. Such techniques include catheter containing radioactive sealed source, radioactive stent, or balloon containing radioactive liquid inside. Each of these methods have their own advantages, inconveniences, problems and risks. Radioisotope may be either beta or gamma emitters. Gamma emitter presents problems for radioprotection but the satisfactory dose distribution may be difficult to obtain using beta emitter. Choice of dose, dose rate and delay between the end of angioplasty and the beginning of brachytherapy is subject to some discuss. Animal experiments using radioisotope have shown reduction in cell proliferation. Human trials showed feasibility, safety of the method and real impact on restenosis prevention. However, long-term efficacy has not been proved because the follow-up of the patients is too short. A randomized trial of 192Ir brachytherapy for prevention of restenosis has recently shown the efficacy in short and median term. However, long term efficiency and secondary effects have not yet been established as the follow up time of this study is still too short. That is why, collaboration between cardiologists and radiotherapists and physicists is indispensable to enable the development of an optimal technique.
Noël
G
G
Centre des tumeurs, hôpital de la Pitié-Salpêtrière, Paris, France.
Feuvret
L
L
Bourhis
J
J
Pousset
F
F
Gerbaulet
A
A
Popowski
Y
Y
Mazeron
J J
JJ
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001918:Brachytherapy / Q000379:methods*; D002455:Cell Division / Q000528:radiation effects; D003131:Combined Modality Therapy; D003324:Coronary Artery Disease / Q000532:radiotherapy* / Q000628:therapy; D003331:Coronary Vessels / Q000528:radiation effects; D004195:Disease Models, Animal; D006801:Humans; D011835:Radiation Protection; D011879:Radiotherapy Dosage; D012008:Recurrence; D013997:Time Factors
Rôle de la curiethérapie endovasculaire dans la prévention de la resténose vasculaire après angioplastie.